(Q24240620)

1

0 references

Marina Romano

2

0 references

Liliana Patrucco

4

0 references

Edgardo Cristiano

Cochrane Database of Systematic Reviews

5

0 references

language of work or name

English

0 references

publication date

20 January 2010

0 references

published in

0 references

issue

1

0 references

page(s)

CD006643

0 references

cites work

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Primary-progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Primary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Primary and transitional progressive MS: a clinical and MRI cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

Primary progressive multiple sclerosis : current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

7 January 2021

Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

7 January 2021

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB3

7 January 2021